FC
YTEN

Fairpointe Capital’s Yield10 Bioscience, Inc. Common Stock YTEN Stock Holding History

Fairpointe Capital’s Portfolio YTEN Stock Details YTEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$251K Buy
+833
New +$282K 0.38% 69

Other funds holding YTEN

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Fairpointe Capital's YTEN Position: Q1 2021 in Review

Fairpointe Capital opened a new position in Yield10 Bioscience, Inc. Common Stock (YTEN) in Q1 2021: 833 shares worth $251K. The stake represents 0.38% of the portfolio and ranks #69 among its holdings.

21 funds tracked by Wall St. Rank hold YTEN as of Q1 2021.

  • Fairpointe Capital held 833 shares of Yield10 Bioscience, Inc. Common Stock worth $251K as of Q1 2021.
  • Yield10 Bioscience, Inc. Common Stock was a new Fairpointe Capital position in Q1 2021.
  • Yield10 Bioscience, Inc. Common Stock made up 0.38% of Fairpointe Capital's portfolio in Q1 2021, its #69 holding.
  • 21 funds tracked by Wall St. Rank held Yield10 Bioscience, Inc. Common Stock as of Q1 2021.

Based on Fairpointe Capital's 13F filing for Q1 2021, filed 13 May 2021.